What is the significance of a Thyroid Imaging, Reporting and Data System (TI-RADS) score of 3?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

TI-RADS 3 thyroid nodules are moderately suspicious for malignancy and should be managed based on their size, with a risk of about 5-10%. According to the American College of Radiology (ACR) Appropriateness Criteria, ultrasound (US) provides high-resolution imaging to characterize the nodule for the risk of malignancy 1. For these nodules, the recommended management depends on size:

  • Nodules measuring 1.5 cm or larger should undergo fine needle aspiration (FNA) biopsy
  • Nodules between 1.0-1.4 cm should be followed with ultrasound in 1 year
  • Nodules smaller than 1.0 cm generally don't require FNA or follow-up This stratified approach balances the risk of missing clinically significant cancer against avoiding unnecessary procedures for low-risk nodules. TI-RADS 3 nodules typically have some suspicious ultrasound features such as hypoechogenicity, solid composition, or irregular margins, but lack the more concerning features seen in higher-risk categories. When following these nodules, significant growth (more than 20% increase in two dimensions with a minimum increase of 2mm) or development of new suspicious features should prompt consideration for biopsy regardless of the initial size, as guided by the ACR TI-RADS and other risk stratification criteria 1.

From the Research

TI-RADS 3 Nodules

  • TI-RADS 3 nodules are considered to have a moderate suspicion of malignancy 2, 3
  • According to the American College of Radiology (ACR) Thyroid Imaging Reporting and Data System (TI-RADS), nodules with a TI-RADS score of 3 should be considered for fine-needle aspiration (FNA) biopsy if they are 2.5 cm or larger in size 2
  • A study published in the AJR American Journal of Roentgenology found that 7 out of 40 malignant nodules that were classified as TI-RADS 3 were 1 cm or larger in size 2
  • Another study published in the European Journal of Radiology found that TI-RADS classification showed a sensitivity of 75% and a negative predictive value of 97.6% in detecting malignant thyroid nodules 4

Management of TI-RADS 3 Nodules

  • The management of TI-RADS 3 nodules depends on their size and other clinical factors 2, 3
  • Nodules with a TI-RADS score of 3 that are 2.5 cm or larger in size should be considered for FNA biopsy 2
  • Smaller nodules with a TI-RADS score of 3 may be monitored with serial ultrasound examinations 3
  • A study published in the La Radiologia Medica found that the TI-RADS system is safe and effective in recommending follow-up for nodules with low TI-RADS scores and benign characteristics 3

Diagnostic Accuracy of TI-RADS

  • The diagnostic accuracy of TI-RADS in detecting malignant thyroid nodules has been evaluated in several studies 2, 3, 4
  • A study published in the AJR American Journal of Roentgenology found that the ACR TI-RADS has a high diagnostic accuracy in detecting malignant thyroid nodules 2
  • Another study published in the European Journal of Radiology found that TI-RADS classification showed a sensitivity of 75% and a negative predictive value of 97.6% in detecting malignant thyroid nodules 4

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.